Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03091673 · ClinicalTrials.gov registry record · Phase 3
Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients
A Phase 3 study, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT03091673 is a Phase 3 study that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT03091673, a Phase 3 study, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen (glucagon injection) in a clinical research center (CRC) or comparable setting.
Interventions
- DRUG Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-03-27 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03091673
The ClinicalTrials.gov registry entry for NCT03091673 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucagon is the first listed.
NCT03091673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03091673 about?
NCT03091673 is a clinical study titled "Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients". This is a sequential efficacy and safety study in pediatric patients with type 1 diabetes. Subjects will be administered insulin to induce a low normal glycemic state and will then receive an age-appropriate dose of G-Pen (glucagon injection) in a clinical research center (CRC) or comparable setting...
What is the current status of trial NCT03091673?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2017-03-27. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT03091673?
The interventions under investigation include: Glucagon (DRUG).
Who is sponsoring clinical trial NCT03091673?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.